Accelerating patient access to oncology medicines with multiple indications in Europe
Background: In recent years, innovation in oncology has created new challenges for pricing and reimbursement systems. Oncology medicines with multiple indications face a number of access challenges: (1) the number of assessments and administrative burden; (2) aligning price to different values of th...
Saved in:
| Main Authors: | R. Lawlor, T. Wilsdon, E. Darquennes, D. Hemelsoet, J. Huismans, R. Normand, A. Roediger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2021.1964791 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?
by: Hannah Armstrong, et al.
Published: (2025-01-01) -
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies
by: Steven Simoens, et al.
Published: (2025-08-01) -
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01) -
Affordability of oncology drugs: accuracy of budget impact estimations
by: Joost W. Geenen, et al.
Published: (2020-01-01) -
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience
by: Chakrapani Balijepalli, et al.
Published: (2025-04-01)